Literature DB >> 18826858

Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study.

A Thijs1, P W B Nanayakkara, P M Ter Wee, P C Huijgens, C van Guldener, C D A Stehouwer.   

Abstract

The high incidence of cardiovascular disease in patients with moderate renal impairment is not fully explained by traditional atherothrombotic risk factors. Independently from these factors, blood platelet activation may increase the cardiovascular disease risk of patients with mild-to-moderate renal impairment. Blood platelet activation has not been studied in nondiabetic patients with mild-to-moderate renal impairment. Therefore, we measured the extent of platelet activation by means of fluorescence cytometry in 93 nondiabetic patients with MDRD-estimated creatinine clearance ranging from 13 - 63 ml/min/1.73 m2. As platelet activation parameters we used the expression of CD62P (P-selectin), CD 63 (glycoprotein 53), PAC-1 (activated fibrinogen receptor), CD42b (von Willebrand factor receptor) and CD41 (fibrinogen receptor) on the platelet surface membrane. The expression of CD62p, CD63 and PAC-1 was statistically significantly inversely related to the estimated glomerular filtration rate in these patients (standardized b -0.28, -0.32 and -0.39, respectively). We conclude that nondiabetic mild-to-moderate renal impairment is associated with blood platelet activation. Whether this contributes to the increased cardiovascular risk in these patients needs further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826858

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  10 in total

1.  Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients.

Authors:  Julia J Scialla; Laura C Plantinga; W H Linda Kao; Bernard Jaar; Neil R Powe; Rulan S Parekh
Journal:  Am J Nephrol       Date:  2011-02-23       Impact factor: 3.754

2.  Plasma metabolomic profiles in different stages of CKD.

Authors:  Vallabh O Shah; Raymond R Townsend; Harold I Feldman; Kirk L Pappan; Elizabeth Kensicki; David L Vander Jagt
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

3.  Pulmonary embolism in patients with CKD and ESRD.

Authors:  Gagan Kumar; Ankit Sakhuja; Amit Taneja; Tilottama Majumdar; Jayshil Patel; Jeff Whittle; Rahul Nanchal
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-26       Impact factor: 8.237

4.  Electron microscopic observation in case of platelet activation in a chronic haemodialysis subject.

Authors:  Marianne Schoorl; Piet C M Bartels; Mareille Gritters; Donna Fluitsma; René Musters; Menso J Nubé
Journal:  Hematol Rep       Date:  2011-10-19

Review 5.  Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.

Authors:  Tawfik Addi; Laetitia Dou; Stéphane Burtey
Journal:  Toxins (Basel)       Date:  2018-10-12       Impact factor: 4.546

6.  The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study.

Authors:  Min Jun; Matthew T James; Braden J Manns; Robert R Quinn; Pietro Ravani; Marcello Tonelli; Vlado Perkovic; Wolfgang C Winkelmayer; Zhihai Ma; Brenda R Hemmelgarn
Journal:  BMJ       Date:  2015-02-03

Review 7.  Molecular Mechanisms Underlying the Cardiovascular Toxicity of Specific Uremic Solutes.

Authors:  Jonathan D Ravid; Vipul C Chitalia
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

8.  Platelet Activity and Cardiovascular Risk in CKD and Peripheral Artery Disease.

Authors:  Lucas B Cofer; Qandeel H Soomro; Yuhe Xia; Elliot Luttrell-Williams; Khrystyna Myndzar; David M Charytan; Jeffrey S Berger
Journal:  Kidney Int Rep       Date:  2022-08-04

Review 9.  Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies.

Authors:  Wern Yew Ding; Stephanie Harrison; Dhiraj Gupta; Gregory Y H Lip; Deirdre A Lane
Journal:  Front Med (Lausanne)       Date:  2020-02-21

10.  Personalized pathology test for Cardio-vascular disease: Approximate Bayesian computation with discriminative summary statistics learning.

Authors:  Ritabrata Dutta; Karim Zouaoui Boudjeltia; Christos Kotsalos; Alexandre Rousseau; Daniel Ribeiro de Sousa; Jean-Marc Desmet; Alain Van Meerhaeghe; Antonietta Mira; Bastien Chopard
Journal:  PLoS Comput Biol       Date:  2022-03-10       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.